Drugs targeting the vascular endothelial growth factor (VEGF), a key regulator of angiogenesis in cancer, can inhibit this mechanism and reduce tumour growth, with favourable outcomes also in terms of survival in different cancer types [108]. The gene discussed is VEGFA; the disease is cancer.